Treatment of insulin-dependent diabetes by hematopoietic stem cell transplantation

Nikoonezhad, Maryam; Lasemi, Maryam Vahdat; Alamdari, Shahram; Mohammadian, Mohsen; Tabarraee, Mahdi; Ghadyani, M; Hamidpour, Mohsen; Roshandel, Elham

doi:10.1016/j.trim.2022.101682

Cited by 5 publications

(2 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given the autoimmune basis of T1D autologous hematopoietic stem cell transplantation (auto-HSCT), a type of auto-transplantation where hematopoietic stem cells are removed from a patient, enriched and introduced back into the patient [27][28][29][30] could regenerate immune tolerance against auto-antigens and be associated with lasting and complete remission of T1D.…”

Section: Genetic Factorsmentioning

confidence: 99%

Type 1 Diabetes and Beta Cells

Owens-Collins

2023

Beta Cells in Health and Disease

View full text Add to dashboard Cite

This book chapter provides an overview of Type 1 diabetes, focusing on the role of beta cells, autoimmunity, genetics, environmental factors, and beta cell health. While genetic factors are also important, environmental factors such as viral infections and dietary factors may trigger or accelerate the development of Type 1 diabetes. Maintaining beta cell health is essential for the prevention and management of Type 1 diabetes. Factors such as glucose toxicity, oxidative stress, and inflammation can contribute to beta cell dysfunction and death. The chapter discusses the transplantation of islet cells both primary and stem cell-derived to treat diabetes. The chapter also outlines the stages of Type 1 diabetes development, starting with the pre-symptomatic stage and progressing to the onset of symptoms, the clinical diagnosis, and the eventual need for insulin therapy. Supporting hormones, such as insulin, glucagon, amylin, somatostatin, and incretin hormones, play critical roles in maintaining glucose homeostasis. Finally, the chapter highlights the effect of food on beta cell health and the effect of various drugs and medications used to manage diabetes.

show abstract

Section: Genetic Factorsmentioning

confidence: 99%

Type 1 Diabetes and Beta Cells

Owens-Collins

2023

Beta Cells in Health and Disease

View full text Add to dashboard Cite

show abstract

“…Over the past two decades, stem cell transplantation has received increased attention in clinical trials as a promising therapy within regenerative medicine for T1DM. While the treatment of T1DM with hematopoietic stem cells was more typical in the 2000s and first half of the 2010s[ 78 ], the most recent studies focus more on the treatment with mesenchymal stem cells (MSCs)[ 13 ]. This modern approach to treat T1DM has several advantages over previous treatment options.…”

Section: Mesenchymal Stem Cell Therapy In T1dmmentioning

confidence: 99%

New therapeutic approaches for type 1 diabetes: Disease-modifying therapies

Nagy¹,

Szekely²,

Somogyi³

et al. 2022

World J Diabetes

View full text Add to dashboard Cite

It has been 100 years since the first successful clinical use of insulin, yet it remains the only treatment option for type 1 diabetes mellitus (T1DM) patients. Advances in diabetes care, such as insulin analogue therapies and new devices, including continuous glucose monitoring with continuous subcutaneous insulin infusion have improved the quality of life of patients but have no impact on the pathogenesis of the disease. They do not eliminate long-term complications and require several lifestyle sacrifices. A more ideal future therapy for T1DM, instead of supplementing the insufficient hormone production (a consequence of β-cell destruction), would also aim to stop or slow down the destructive autoimmune process. The discovery of the autoimmune nature of type 1 diabetes mellitus has presented several targets by which disease progression may be altered. The goal of disease-modifying therapies is to target autoimmune mechanisms and prevent β-cell destruction. T1DM patients with better β-cell function have better glycemic control, reduced incidence of long-term complications and hypoglycemic episodes. Unfortunately, at the time symptomatic T1DM is diagnosed, most of the insulin secreting β cells are usually lost. Therefore, to maximize the salvageable β-cell mass by disease-modifying therapies, detecting autoimmune markers in an early, optimally presymptomatic phase of T1DM is of great importance. Disease-modifying therapies, such as immuno- and regenerative therapies are expected to take a relevant place in diabetology. The aim of this article was to provide a brief insight into the pathogenesis and course of T1DM and present the current state of disease-modifying therapeutic interventions that may impact future diabetes treatment.

show abstract

Mesenchymal Stem Cell Transplantation in Type 1 Diabetes Treatment: Current Advances and Future Opportunity

Liu,

Wan,

Zheng

et al. 2024

CSCR

View full text Add to dashboard Cite

Type 1 Diabetes (T1D) is characterized by hyperglycemia, and caused by a lack of insulin secretion. At present there is no cure for T1D and patients are dependent on exogenous insulin for lifelong, which seriously affects their lives. Mesenchymal stem cells (MSCs) can be differentiated to β cell-like cells to rescue the secretion of insulin and reconstruct immunotolerance to preserve the function of islet β cells. Due to the higher proportion of children and adolescents in T1D patients, the efficacy and safety issue of the application of MSC’s transplant in T1D was primarily demonstrated and identified by human clinical trials in this review. Then we clarified the mechanism of MSCs to relieve the symptom of T1D and found out that UC-MSCs have no obvious advantage over the other types of MSCs, the autologous MSCs from BM or menstrual blood with less expanded ex vivo could be the better choice for clinical application to treat with T1D through documentary analysis. Finally, we summarized the advances of MSCs with different interventions such as genetic engineering in the treatment of T1D, and demonstrated the advantages and shortage of MSCs intervened by different treatments in the transplantation, which may enhance the clinical efficacy and overcome the shortcomings in the application of MSCs to T1D in future.

show abstract

Treatment of insulin-dependent diabetes by hematopoietic stem cell transplantation

Cited by 5 publications

References 49 publications

Type 1 Diabetes and Beta Cells

Type 1 Diabetes and Beta Cells

New therapeutic approaches for type 1 diabetes: Disease-modifying therapies

Mesenchymal Stem Cell Transplantation in Type 1 Diabetes Treatment: Current Advances and Future Opportunity

Contact Info

Product

Resources

About